Breakthrough: Northwestern’s NU-9 Compound Shows Promise for Preventing Alzheimer’s Disease

Researchers at Northwestern University have developed a novel compound that could potentially prevent Alzheimer’s disease before symptoms appear, similar to how cholesterol medication works to prevent heart attacks.

Key Findings of the Research

Scientists discovered a previously unknown subtype of brain protein called ACU193+ AβOs (a form of amyloid beta oligomers) that is associated with brain inflammation occurring before Alzheimer’s diagnosis. The team’s synthetic compound, NU-9, effectively reduced the presence of this toxic protein in mice predisposed to develop Alzheimer’s disease.

In the experiment, researchers administered an oral dose of NU-9 to mice for 60 days before they developed Alzheimer’s. The results showed that NU-9 significantly decreased the presence of the harmful protein subtype and reduced associated inflammation.

Preventative Approach to Alzheimer’s

Richard Silverman, a chemistry professor at Northwestern who invented NU-9, compared the potential treatment approach to cholesterol management. Just as people take medication to lower cholesterol before experiencing a heart attack, individuals with biomarkers signaling Alzheimer’s disease could potentially take NU-9 preventatively.

William Klein, the paper’s principal investigator, described the results as “stunning” and emphasized that combining early diagnostic tools with a drug that could halt disease progression is the ultimate goal.

Broader Applications

Beyond Alzheimer’s disease, NU-9 has shown promise in treating other neurological conditions, including Amyotrophic Lateral Sclerosis (ALS) and potentially frontotemporal degeneration. All three conditions involve the appearance of toxic proteins in the brain.

Next Steps

The research team plans to analyze NU-9’s effectiveness in later stages of Alzheimer’s disease. This work represents an important step toward developing treatments that address the underlying causes of neurodegenerative diseases rather than just managing symptoms.

The findings were published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, marking a significant advancement in the field of neurodegenerative disease research.